Navigation Links
FDA Approves New Kind of Insomnia Drug
Date:8/14/2014

WEDNESDAY, Aug. 13, 2014 (HealthDay News) -- A new prescription insomnia drug that's the first of its kind was approved by the U.S. Food and Drug Administration on Wednesday.

Belsomra (suvorexant) tablets are approved to treat patients with insomnia, which means they have difficulty falling and staying asleep.

The new sleep drug is called an orexin receptor antagonist and it works by altering the action of the brain chemical orexin, which helps regulate the sleep-wake cycle and also helps keep people awake.

"To assist health care professionals and patients in finding the best dose to treat each individual patient's sleeplessness, the FDA has approved Belsomra in four different strengths -- 5, 10, 15 and 20 milligrams [mg]," Dr. Ellis Unger, director of the Office of Drug Evaluation I in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"Using the lowest effective dose can reduce the risk of side effects, such as next-morning drowsiness," he added.

Belsomra should be taken only once a night, within 30 minutes of going to bed, and with at least seven hours remaining before the planned time of waking. The total dose should not exceed 20 mg once daily, the FDA said.

The drug's approval was based on the findings of three clinical trials that included more than 500 people, the agency said. The results showed that people who took Belsomra fell asleep faster and spent less time awake during the night than those who took a placebo.

Belsomra was not compared to other insomnia drugs, so it's not known if there are differences in safety or effectiveness, the FDA said.

The agency asked Belsomra maker Merck, Sharpe & Dohme Corp. to study next-day driving performance in people who had taken the drug. Both men and women had impaired driving skills when they took the 20-mg dose, which means that people who take that maximum dose should be cautioned to avoid driving or other activities that req
'/>"/>

Copyright©2014 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. FDA Approves Highly Accurate At-Home Colon Cancer Test
2. FDA Approves New Type 2 Diabetes Drug
3. FDA Approves New Treatment for People With COPD
4. FDA Approves Hard-to-Abuse Narcotic Painkiller
5. NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors
6. FDA approves many drugs that predictably increase heart and stroke risk
7. FDA approves first targeted drug for advanced stomach cancer
8. Augusta Maine Chocoholic, Adam Green, Approves Xocai's "Change Your Chocolate" Success to Demand for Raw Blueberry in Nagoya, Japan and Taipei, Taiwan
9. German Research Foundation approves research unit to study extreme experiences in life
10. FDA Approves Memory Shape Silicone Implants
11. Branches' Ways to Work Program Approves 60th Car Loan
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves New Kind of Insomnia Drug
(Date:11/26/2014)... 26, 2014 The family foundation of ... the Mesothelioma Applied Research Foundation (Meso Foundation), half of ... Patient Travel Grant Program . The focus area ... create grant partnerships with organizations that can generate transformational ... Schulze is the founder and chairman emeritus of Best ...
(Date:11/26/2014)... 26, 2014 German scientists say carbon-based ... can cause mesothelioma that looks and acts similar to ... article on the research. Click here to read ... for Toxicology and Experimental Medicine in Hannover injected 500 ... of the rats eventually developed mesothelioma , how ...
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... For those with a New Year’s resolution to get ... at the University of Colorado Anschutz Health and Wellness ... The 45- 60 minute classes have just started and are ... club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition ... at fast results , By focusing on low weight ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... ATLANTA, Sept. 8 Craneware, Inc. (AIM: CRW.L), a leader in sustainable financial improvement ... ended June 30, 2009. , , Financial Highlights , ... in the year totaling $43.2m (FY08: $25.7m), 68% up from the previous year, contributing ... to $23.0m (FY08: $18.7m) , 51% ...
... , , WASHINGTON, Sept. 8 More ... in scrubs and lab coats this week to bring an angry message ... The doctors, all traveling as individuals and at their own expense, will ... meet with the doctors of Congress, including Tom Price, M.D. (GA) and ...
... , , , ... and Walmart,s Leslie Dach to discuss areas of bipartisan agreement in ... The Bipartisan Policy Center (BPC) and Better Health Care Together ... agreement among political, business and labor leaders in the health reform ...
... maintained in mice given HDAC inhibitors, study finds , TUESDAY, ... cancer drug might be able to restore day-to-day memory ... common form of dementia among the elderly, is expected to ... sign is loss of short-term memory. , "People often joke ...
... , BRISTOL, Va. and BIRMINGHAM, Ala., ... (NYSE: HLS ) today announced that a joint venture ... of public need (COPN) to open a new inpatient rehabilitation hospital ... Bristol and throughout Southwest Virginia to have access to comprehensive, high-quality ...
... , NEW YORK, Sept. 8 ... its catalogue. , , Lung Cancer ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , This report ... Millions of US$. The US market for Non-Small Cell Lung Cancer ...
Cached Medicine News:Health News:Craneware Announces Fiscal Year-End Results 2Health News:Craneware Announces Fiscal Year-End Results 3Health News:Dr. 'Smith' Comes to Washington: Angry Physicians From All 50 States Rally in DC on Sept 10 2Health News:Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 2Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 3Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 4Health News:Wellmont, HealthSouth Form Joint Venture to Open a New Rehabilitation Hospital in Southwest Virginia 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10
(Date:11/24/2014)... , Nov. 24, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the Piper ... 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ... New York . A live audio webcast ... section of Arena,s website at www.arenapharm.com . A replay ...
(Date:11/24/2014)... , Nov. 24, 2014  Marta Rendon, MD, founder of ... Boca Raton , FL and international key opinion leader in ... the United States to attend the ... Istanbul, Turkey . Here, at this gathering of over ... world renowned facial plastic surgery experts from Asia ...
(Date:11/24/2014)... CLEVELAND , Nov. 24, 2014  Surgical Theater, ... at the November 24 th opening of ... IRCCS Istituto Neurologico Nazionale "C. Besta." The SuRgical Planner ... be showcased at the event for their 3D navigation ... Dr. Joshua Bederson , Professor and Chair, Department ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... ,Oct. 19, 2011 Innocoll, Inc. announced it has ... Pharma in China for CollaGUARD surgical adhesion barrier for ... surgery.   Dr. Michael Myers, President and ... China is becoming an increasingly important and dynamic market ...
... YORK, Oct. 19, 2011 Reportlinker.com announces that ... its catalogue: Syncria (Type ... http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Forecasts to 2020 Summary ...
Cached Medicine Technology:Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 2Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5